ADC Therapeutics (ADCT) Competitors

Tyra Biosciences (NASDAQ:TYRA) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, community ranking, risk, analyst recommendations, earnings, dividends and profitability.

Do analysts recommend TYRA or ADCT?

Tyra Biosciences presently has a consensus price target of $30.83, indicating a potential upside of 194.21%. ADC Therapeutics has a consensus price target of $7.75, indicating a potential upside of 436.33%. Given ADC Therapeutics' higher probable upside, analysts clearly believe ADC Therapeutics is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
ADC Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community believe in TYRA or ADCT?

ADC Therapeutics received 26 more outperform votes than Tyra Biosciences when rated by MarketBeat users. However, 76.60% of users gave Tyra Biosciences an outperform vote while only 68.89% of users gave ADC Therapeutics an outperform vote.

Company	Underperform	Outperform
Tyra Biosciences	Outperform Votes 36 76.60%	Underperform Votes 11 23.40%
ADC Therapeutics	Outperform Votes 62 68.89%	Underperform Votes 28 31.11%

Is TYRA or ADCT more profitable?

Tyra Biosciences has a net margin of 0.00% compared to ADC Therapeutics' net margin of -300.00%. ADC Therapeutics' return on equity of 0.00% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-24.56%	-23.31%
ADC Therapeutics	-300.00%	N/A	-61.33%

Does the media refer more to TYRA or ADCT?

In the previous week, Tyra Biosciences had 1 more articles in the media than ADC Therapeutics. MarketBeat recorded 3 mentions for Tyra Biosciences and 2 mentions for ADC Therapeutics. Tyra Biosciences' average media sentiment score of 1.40 beat ADC Therapeutics' score of -0.33 indicating that Tyra Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk and volatility, TYRA or ADCT?

Tyra Biosciences has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500.

Which has stronger valuation & earnings, TYRA or ADCT?

Tyra Biosciences has higher earnings, but lower revenue than ADC Therapeutics. Tyra Biosciences is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$69.13M	-$1.51	-6.94
ADC Therapeutics	$70.84M	2.02	-$240.05M	-$1.65	-0.88

Do institutionals and insiders believe in TYRA or ADCT?

84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 15.4% of Tyra Biosciences shares are owned by company insiders. Comparatively, 4.1% of ADC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Tyra Biosciences beats ADC Therapeutics on 10 of the 16 factors compared between the two stocks.